The START Center for Cancer Research’s Post

Excited to share START’s first poster presentation of the year from #ASCOGI! Sree Chandana, MD, Principal Investigator at START Midwest, presented a Trials in Progress poster for the Zymeworks Inc. ZW251 study. The study is evaluating ZW251, an antibody–drug conjugate targeting glypican-3 (GPC3), in participants with advanced cancers, including hepatocellular carcinoma (HCC). Notably, START Midwest treated the first patient on this study. Congratulations to Dr. Chandana, the START Midwest team, and Zymeworks!